Overview

TWB-103 for Treating Lower Limb Ulcers on Patients With DM

Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
Primary Objective: To assess the safety profile of TWB-103 administered to subjects with diabetic lower limb ulcers Secondary Objective: To explore the efficacy of TWB-103 administered to subjects with diabetic lower limb ulcers
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Transwell Biotech Co., Ltd.